Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SCALA-TK-CM: Semaglutide and CArdiometabolic Real-Life Atlas - TürKiye CardioMetabolic Epidemiology Study: A Retrospective Real-World Cohort Study

NCT07781371 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07781371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07781371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SCALA-TK-CM: Semaglutide and CArdiometabolic Real-Life Atlas - TürKiye CardioMetabolic Epidemiology Study: A Retrospective Real-World Cohort Study
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Active, not recruiting
Start date
August 20, 2026
Completion date
November 2, 2026
Enrollment
100,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease (cvd), chronic kidney disease (ckd), dyslipidemia, metabolic dysfunction-associated steatotic liver disease (masld), obesity, prediabetes, type 2 diabetes (t2d)